X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
XORLO (proprietary oxypurinol formulation) is in under development for the treatment of individuals with progressing autosomal dominant polycystic kidney disease (ADPKD).
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: Xorlo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
XORLO (proprietary oxypurinol formulation) is in under development for the treatment of individuals with progressing autosomal dominant polycystic kidney disease (ADPKD).
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: Xorlo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, which results in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRX-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, which results in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, resulting in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
XRx-008 (oxypurinol) inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid, which results in a decrease in the concentrations of uric acid in the blood and urine.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
XORTX’s lead program XRx-008 is designed to deliver the xanthine oxidase inhibitor (“XOI”) oxypurinol at concentrations sufficient to substantially inhibit aberrant purine metabolism in the kidneys of individuals with progressing kidney disease due to ADPKD.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
XORTX’s XRx-008 therapeutic development program for ADPKD, is advancing a proprietary composition of xanthine oxidase inhibitor, to manage aberrant purine metabolism and chronically high serum uric acid concentration.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
XRx-008 is designed to deliver xanthine oxidase inhibitor oxypurinol at concentrations sufficient to substantially inhibit aberrant purine metabolism in kidney of individuals with progressing kidney disease due to ADPKD inhibit production of uric acid in circulation.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
The presentation will report that XORTX's XRx-008 (oxypurinol) formulation of Xanthine Oxidase inhibitor can substantially and significantly block the increase in kidney size associated with high circulating uric acid in a rodent model of polycystic kidney disease.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRX-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
The company intends to use the proceedings to further develop and advance its pipeline of product candidates, including the conduct of clinical studies and initiation of a registration trial (Phase 3) for its lead program XRx-008 (oxypurinol) for the treatment of ADPKD.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 07, 2022
Details:
The offering will support to increase the liquidity and raise capital to further develop and advance the pipeline of product candidates, including the conduct of clinical studies and initiation of a registration trial (Phase 3) for lead program XRx-008 having Oxypurinol.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 04, 2022
Details:
R&D activities included manufacturing clinical quality GMP oxypurinol (XRx-008), finalizing formulation of drug product, and non-clinical studies including the characterization of improved oral bioavailability of its proprietary formulation in animal models.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
XRx-008 (oxypurinol), is advancing a proprietary composition of xanthine oxidase inhibitor, to manage aberrant purine metabolism and chronically high serum uric acid concentration.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Experimental data of XRx-008 (oxypurinol) from animal studies suggest that processes such as inflammation, renin-angiotensin-aldosterone system, insulin resistance, and endothelial dysfunction may be involved in the pathogenesis of the disease.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Xrx-008 (oxypurinol), that target xanthine oxidase to inhibit production of uric acid, is being developed as a treatment of progressive kidney disease in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
XRx-008 (oxypurinol) for ADPKD, is advancing a proprietary composition of xanthine oxidase inhibitor, to manage aberrant purine metabolism and chronically high serum uric acid concentration.
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
XRx-101 (a novel formulation of uric acid lowering agent/Oxypurinol) with the ability to decrease acute kidney, as a treatment aimed at decreasing acute kidney disease and organ injury associated with viral infection.
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: XRx-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Following administration of first dose of drug, blood sampling and bioanalytical evaluation will be conducted to characterize pharmacokinetics and bioavailability of XRx-008 novel proprietary formulations of oxypurinol.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
XORTX is focused on advancing XRx-008 through bridging pharmacokinetic, as well as registration clinical trials for the treatment of ADPKD. At the present time, very few approved therapeutic options exist to treat progressive kidney disease in individuals due to this disease.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Based on the studies, Oxypurinol formulation, XRx-101, has the potential to be a front-line treatment for severe cases of Coronavirus and this therapy has the ability to decrease morbidity and mortality in hospitalized patients.
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: XRx 101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
XRx-008, target xanthine oxidase to inhibit production of uric acid is being developed as a treatment of progressive kidney disease in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Lead Product(s): Oxypurinol
Therapeutic Area: Nephrology Product Name: XRx-008
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Company to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19.
Lead Product(s): Oxypurinol
Therapeutic Area: Genetic Disease Product Name: XRx-008
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Altasciences Company Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
The FDA response provided clear feedback on the proposed plan and outlined the critical steps to test XRx-101 in patients with COVID-19 infection to treat acute kidney injury (“AKI”).
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
This filing initiates formal communications with the U.S. FDA regarding development of the Company’s proprietary formulation of XRx-101 (Oxypurinol) for the treatment and prevention of acute kidney injury (AKI) associated with COVID-19 coronavirus infection.
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
XRx-101 is a proprietary of xanthine oxidase inhibitor oxypurinol. The study provides clues about the potential of XRx-101 as a treatment to suppress the severity of the COVID-19 infection.
Lead Product(s): Oxypurinol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Icahn School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 04, 2020
Details:
XORTX continues to seek non-dilutive funding for XRx-008 and XRx-101 programs with several granting agencies.
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
Lonza Pharma will be resposible for manufacturing of active pharmaceutical ingredient for XRx-101 and XRx-008 in response to support the drug development and clinical trial process for COVID-19.
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xortx Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2020
Details:
Company is exploring the potential of using XRx-101 as a novel treatment for acute kidney and lung injury accompanying Coronavirus infection and specifically for the COVID-19 infection.
Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
